Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report

Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report

Abstract Background Targeted therapies are a standard of care for first-line treatment of Anaplastic lymphoma kinase (ALK)-rearranged non small cell lung cancer (NSCLC). Giving the rapid pace of drug discovery and development in this area, reporting of adverse effects of ALK inhibitors is crucial. H...

Full description

Bibliographic Details
Main Authors: F. Guisier, N. Piton, M. Bellefleur, N. Delberghe, G. Avenel, E. Angot, O. Vittecoq, M. Ould-Slimane, H. Morisse-Pradier, M. Salaun, L. Thiberville
Format: Article
Language:English
Published: BMC 2020-01-01
Series:BMC Cancer
Subjects:
ALK-rearranged NSCLC
ALK inhibitors
Crizotinib
Ceritinib
Drug toxicity
Osteitis
Online Access:https://doi.org/10.1186/s12885-019-6486-3

Internet

https://doi.org/10.1186/s12885-019-6486-3

Similar Items